

Ref. No: 0561
Date: 05/01/24
Subject: Usage of Biologic and Biosimilar Products

REQUEST

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Drug	No. Patients
Abatacept [Orencia]	111
Adalimumab [Humira]	53
Adalimumab Biosimilars	356
Apremilast [Otezla]	6
Baricitinib [Olumiant]	111
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	32
Etanercept [Enbrel]	44
Etanercept Biosimilars	242
Filgotinib [Jyseleca]	22
Golimumab [Simponi]	52
Guselkumab [Tremfya]	<5
Infliximab [Remicade]	<5
Infliximab Biosimilars	27
Ixekizumab [Taltz]	6
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	<5
Rituximab Biosimilars	44
Sarilumab [Kevzara]	<5
Secukinumab [Cosentyx]	70
Tocilizumab [Ro Actemra]	53
Tocilizumab Biosimilars	0
Tofacitinib [Xeljanz]	36
Upadacitinib [Rinvoq]	17
Ustekinumab [Stelara]	11

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the

lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

2. **Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.**

Drug	No. Patients
Adalimumab [Humira]	<5
Adalimumab Biosimilars	52
Certolizumab [Cimzia]	<5
Etanercept [Enbrel]	0
Etanercept Biosimilars	18
Golimumab [Simponi]	<5
Infliximab [Remicade]	0
Infliximab Biosimilars	<5
Ixekizumab [Taltz]	0
Secukinumab [Cosentyx]	13
Tofacitinib [Xeljanz]	0
Upadacitinib [Rinvoq]	<5

Section 12: cost of compliance exceeds the appropriate limit

The data provided for question two relates only to Southport and Ormskirk sites. This data is not centrally recorded at St Helens and Knowsley and would require a manual review of records, which we estimate would exceed the appropriate time limits.

Under Section 12 of the Freedom of Information Act, Mersey and West Lancashire Teaching Hospitals NHS Trust does not have to comply with a request where it is estimated that the cost of compliance would exceed the appropriate limit of £450. The appropriate limit is specified within the regulations and represents the estimated cost of one person spending 2½ working days answering the request, either wholly or partially.